1. |
Robbins RJ. Somatostatin and cancer [J]. Metabolism,1996; 45(8 Suppl 1)∶98.
|
2. |
Srikant CB.Cell cycle dependent induction of apoptosis by somatostatin analog SMS201995 in AtT20 mouse pituitary cells [J]. Biochem Biophys Res Commun,1995; 209(2)∶400.
|
3. |
Reubi JC. Clinical relevance of somatostatin receptor imaging [J]. Eur J Endocrinol,1994; 131(6)∶575.
|
4. |
Reubi JC, Laissue JA. Multiple actions of somatostatin in neoplastic disease [J]. Trends Pharmacol Sci,1995; 16(3)∶110.
|
5. |
Sharma K, Patel YC, Srikant CB. Subtypeselective induction of wildtype p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3 [J]. Mol Endocrinol,1996; 10(12)∶1688.
|
6. |
Patel YC, Panetta R, Escher E,et al. Expression of multiple somatostatin receptor genes in AtT20 cells. Evidence for a novel somatostatin28 selective receptor subtype [J]. J Biol Chem, 1994; 269(2)∶1506.
|
7. |
Weinstein IB. The origins of human cancer: molecular mechanisms of carcinogenesis and their implications for cancer prevention and treatmenttwentyseventh G.H.A. Clowes memorial award lecture [J]. Cancer Res,1988; 48(15)∶4135.
|
8. |
Stanbridge EJ. The reemergence of tumor suppression [J]. Cancer Cells, 1989; 1(1)∶31.
|
9. |
Lebovitz RM, Lieberman MW. Modulation of cellular genes by oncogenes [J]. Prog Nucleic Acid Res Mol Biol, 1988; 35∶73.
|
10. |
Pinto A, Attadia V, Rosati R,et al.Differentiation of human leukaemic cell lines and fresh leukaemia cells by low dose AraC: monitoring by expression of cmyc and cfos oncogenes [J]. Med Oncol Tumor Pharmacother, 1988; 5(2)∶91.
|